Abiopharma

AGIOS PHARMACEUTICALS, INC. (AGIO) Reports the reporting period Financial Results AGIOS PHARMACEUTICALS, INC. (AGIO) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 1319
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 1045492
  • world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial
  • stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.Available Information about Agios To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address. Cautionary Note Regarding Forward
  • Looking Statements This press release contains forward